Holland Capital Invests in Curess
Amsterdam, June 20th, 2024 – Holland Capital participates in Curess, a leading organization in youth care focused on systemic family support. Through the collaboration with Holland Capital, further growth and development can be achieved.
Systemic Family Support
Curess offers specialized ambulatory youth care (such as intensive systemic guidance, ambulatory emergency help, perspective research, and co-parenting investigations) and focuses on strengthening families through practical and directly applicable assistance. Curess operates without waiting lists and can scale its operations up and down quickly, to deliver the desired care swiftly and with high quality. The organization achieves this by applying self-developed software that supports core processes (such as planning) and thus reduces administrative pressure.
Strategic Parntership
With this strategic partnership, Curess has found a partner to achieve its ambitious strategic goals.
Eddy de Bruin, CEO of Curess, states: “With the support of Holland Capital, we can realize our ambitions and help even more young people and families. With their expertise and resources, we are better equipped to significantly increase our impact in youth care. We are committed to providing the necessary support to families to learn to live together better, without waiting lists, through our dedicated professionals.”
Margot Engels, Healthcare Partner at Holland Capital, adds: “We are proud to add Curess to our portfolio. Curess provides crucial support to families in an innovative way, and we look forward to working together on their growth ambitions and further professionalization of their services. Our shared vision is to provide the best possible care and support.”
About Curess
With over 200 registered professionals, Curess offers specialized ambulatory youth care to young people and families to ensure they can live together better. By utilizing personal and innovative methods, Curess strives for a safe and supportive environment for children and their families. Curess is active in the regions of Twente, Midden-IJssel, Oost-Veluwe, Noord-Veluwe, Achterhoek, and Zuid-Drenthe
About Holland Capital
Holland Capital has been responsibly and successfully investing in promising Dutch and German SMEs with growth ambitions for over 40 years. The team understands entrepreneurship and strives for an open, sustainable, and professional relationship with the management teams of the companies they invest in, with the common goal of realizing growth. Holland Capital has offices in Amsterdam and Düsseldorf. With specialized sector teams, it focuses on the Healthcare, Technology, and Agrifood-Tech sectors. They understand the dynamics and opportunities, and have an extensive network in these sectors.
The participation in Curess fits within Holland Capital’s strategy to invest in companies that contribute to societal challenges and create value for society. With this investment, Holland Capital takes an important step in further strengthening its portfolio within the healthcare sector.
Sirius Medical announces CE mark for Pintuition: a non-radioactive localization system to improve breast cancer surgery
Sirius Medical announces CE mark for Pintuition: a non-radioactive localization system to improve breast cancer surgery Eindhoven, June 16, 2020 – Sirius Medical, a MedTech startup, announced that it has received CE mark approval for Sirius Pintuition. With its debut...
Sirius Medical ontvangt CE-markering voor Pintuition: een niet radioactief lokalisatiesysteem ter verbetering van borstkankeroperaties
Sirius Medical ontvangt CE-markering voor Pintuition: een niet-radioactief lokalisatiesysteem ter verbetering van borstkankeroperaties Eindhoven, 16 Juni 2020 Sirius Medical, een medtech startup, kondigt aan dat het CE-markering heeft ontvangen voor Sirius...
CytoSMART to donate 100 live-cell imaging systems to assist COVID-19 researchers
CytoSMART to donate 100 live-cell imaging systems to assist COVID-19 researchers Eindhoven, The Netherlands - 22 April 2020, - CytoSMART Technologies is to donate 100 mini live-cell imaging systems to researchers in high containment labs worldwide. Labs working to...
Yenlo benoemd tot Platinum VAR, de hoogste WSO2 Reseller status
Yenlo benoemd tot Platinum VAR, de hoogste WSO2 Reseller statusYenlo is benoemd tot WSO2 Platinum Value-Added Reseller als erkenning voor de behaalde successen en het leveren van de beste opensource integratie- en API-managementoplossingen gebaseerd op het WSO2...
Yenlo Achieves Highest WSO2 Reseller Status as a Platinum VAR
Yenlo Achieves Highest WSO2 Reseller Status as a Platinum VAR Yenlo was named a WSO2 Platinum Value-Added Reseller in recognition of its success in growing global customer adoption and delivering best-in-class open source integration and API management solutions based...
Portfolio company Inno4Life sold to the Swiss company Dec Group
Portfolio company Inno4Life sold to the Swiss company Dec Group Amsterdam, April 16, 2020 - Earlier this month, Inno4Life, a manufacturer of machines for the pharmaceutical industry, was sold to the Swiss Dec Group. Inno4Life's management will remain actively involved...
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl